Abstracts tagged "pseudogout"

Abstract Number: 0580 • ACR Convergence 2020
Risk of Severe Acute Localized Reactions for Different Intra-Articular Hyaluronic Acid Knee Injections in a Real World Setting
Kevin Ong¹, Jack Farr², Louis McIntyre³, Andrew Gudeman², Iain Murray⁴, Charles Hummer⁵, Wilson Ngai⁶, Heather Good⁷, Edmund Lau⁸ and Roy Altman⁹, ¹Exponent, Philadelphia, ²Indiana University Department of Orthopaedic Surgery, Indianapolis, ³US Orthopedics, Tarrytown, ⁴Department of Orthopaedics, The University of Edinburgh, Edinburgh, United Kingdom, ⁵Premier Orthopaedics and Sports Medicine, Glen Mills, ⁶Sanofi US, Bridgewater, ⁷Sanofi US, Bridgewater, FL, ⁸Exponent, Menlo Park, ⁹David Geffen School of Medicine, University of California, Agua Dulce, CA
Background/Purpose: Case reports of severe acute localized reactions (SALR) following intra-articular (IA) hyaluronic acid (HA) injections for knee osteoarthritis (OA) have been described. These have…
Abstract Number: 0670 • ACR Convergence 2020
Risk Factors for Pseudogout: An Electronic Medical Record Case-Control Study
Sara Tedeschi¹, Kazuki Yoshida¹, Weixing Huang² and Daniel H. Solomon¹, ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: Prior studies of calcium pyrophosphate crystal deposition disease (CPPD) epidemiology either focused on the entire spectrum of CPPD or identified patients with its acute…
Abstract Number: 365 • 2019 ACR/ARP Annual Meeting
Classifying Pseudogout Using Machine Learning Approaches with Electronic Health Record Data
Sara K. Tedeschi¹, Tianrun Cai ², Zeling He ³, Yuri Ahuja ⁴, Chuan Hong ⁵, Katherine Yates ⁴, Kumar Dahal ², Chang Xu ³, Houchen Lyu ², Kazuki Yoshida ⁶, Daniel Solomon ⁷, Tianxi Cai ⁵ and Katherine Liao ², ¹Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, Boston, MA, ⁴Harvard Medical School, Boston, ⁵Harvard T.H. Chan School of Public Health, Boston, ⁶Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, ⁷Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Identifying pseudogout in large administrative datasets has been difficult due to lack of specific billing codes for this acute subtype of calcium pyrophosphate (CPP)…
Abstract Number: 901 • 2019 ACR/ARP Annual Meeting
Sensitivity of Dual-Energy CT, Ultrasound, and X-Ray for Pseudogout: A Pilot Study
Sara K. Tedeschi¹, Daniel Solomon ², Kathleen Vanni ³, Dong Suh ³ and Stacy Smith ⁴, ¹Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ²Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston
Background/Purpose: Advanced imaging modalities such as ultrasound (US) and dual-energy CT (DECT) can help diagnose crystalline arthritis. DECT is a highly sensitive and specific modality…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].